We are live on ! Find out more
CSCI

COSCIENS Biopharma Inc. Common Stock
CSCI

Delisted

CSCI was delisted on the 3rd of September, 2025.

Back to rankings

9 hedge funds and large institutions have $1.22M invested in COSCIENS Biopharma Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

13% more funds holding

Funds holding: 8 → 9 (+1)

10% more capital invested

Capital invested by funds: $1.1M → $1.22M (+$113K)

Holders
9
Holders Change
+1
Holders Change %
+12.5%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$127K
2
Renaissance Technologies
Renaissance Technologies
New York
+$95.3K
3
Deutsche Bank
Deutsche Bank
Germany
+$63.6K
4
BIT
BlackRock Institutional Trust
California
+$47.7K

Top Sellers

Rank Fund Capital Flow
1
RCM
Rotella Capital Management
Washington
-$30K
2
TRCT
Tower Research Capital (TRC)
New York
-$6K
3
Bank of America
Bank of America
North Carolina
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$671K +$95.3K +6 +16%
BIT
2
BlackRock Institutional Trust
California
$153K +$47.7K +3 +43%
Deutsche Bank
3
Deutsche Bank
Germany
$145K +$63.6K +4 +67%
Cambridge Investment Research Advisors
4
Cambridge Investment Research Advisors
Iowa
$120K +$127K +8 New
VKH
5
Virtu KCG Holdings
New York
$33K +$31.8K +2 New
HK
6
Horizon Kinetics
New York
$26K – – –
Fifth Third Bancorp
7
Fifth Third Bancorp
Ohio
$25K – – –
Morgan Stanley
8
Morgan Stanley
New York
$19K – – –
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
$8K – – –
Bank of Montreal
10
Bank of Montreal
Ontario, Canada
$7K – – –
MFS
11
MSI Financial Services
Massachusetts
$4K – – –
Invesco
12
Invesco
Georgia
$3K – – –
AllianceBernstein
13
AllianceBernstein
Tennessee
$2K – – –
Ameriprise
14
Ameriprise
Minnesota
$1K – – –
Creative Planning
15
Creative Planning
Kansas
$1K – – –
RCM
16
Rotella Capital Management
Washington
– -$30K -2 Closed
Bank of America
17
Bank of America
North Carolina
– -$3K – –
TRCT
18
Tower Research Capital (TRC)
New York
– -$6K – –

CSCI Hedge Fund Activity: Q3 2013 in Review

9 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q3 2013, worth a combined $1.22M — up 10% from $1.1M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CSCI positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $127K. The largest seller was Rotella Capital Management, exiting entirely with an estimated $30K sold.

  • 9 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q3 2013, up from 8 in Q2 2013.
  • Funds reported $1.22M of COSCIENS Biopharma Inc. Common Stock stock for Q3 2013, up 10% quarter-over-quarter.
  • 2 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q3 2013 and 1 closed out, a net change of +1 holder.
  • The largest COSCIENS Biopharma Inc. Common Stock buyer in Q3 2013 was Cambridge Investment Research Advisors, an estimated $127K added.
  • The largest COSCIENS Biopharma Inc. Common Stock seller in Q3 2013 was Rotella Capital Management, an estimated $30K sold.

Based on aggregated 13F filings for Q3 2013.